Table 1.

Patient, disease and treatment characteristics

Parameter	Spacer cohort (n=79)	Non-spacer cohort (n=136)
Median age	68.9	69.1
Clinical Stage, n (%)
T1	48 (60.8)	72 (52.9)
T2	19 (24.1)	38 (27.9)
T3	1 (1.3)	7 (5.2)
Recurrent	11 (13.9)	19 (14.0)
Gleason Score, n (%)
3+3	4 (5.1)	11 (8.1)
3+4	33 (41.8)	70 (51.9)
4+3	24 (30.4)	27 (20.0)
4+4	9 (11.4)	11 (8.1)
4+5	7 (8.9)	15 (11.1)
5+4	2 (2.5)	1 (0.08)
Pre-treatment PSA (ng/ml) [range]	7.2 [1.1 – 211.0]	6.6 [0.5 – 88.7]
Baseline IPSS [range]	5 [0 – 20]	6 [0 – 30]
LDR implant intent, n (%)
Monotherapy	26 (32.9)	44 (32.3)
Combination with external beam	42 (53.2)	73 (53.7)
Salvage monotherapy	11 (13.9)	19 (14.0)

PSA – prostate specific antigen; IPSS – international prostate symptom score; LDR – low dose rate